ArticleBMC microbiology2026
Therapeutic modulation of the gut-liver axis with faecalibacterium prausnitzii in metabolic dysfunction-associated steatohepatitis.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundFaecalibacterium prausnitzii (F. prausnitzii) has attracted interest in recent research regarding its possible involvement in metabolic dysfunction-associated steatotic liver disease (MASLD). However, their causal relationship is still unclear.
methodsMicrobial biomarkers of gut microbiota associated with obesity-related phenotypes were identified from the GMrepo database. Information was retrieved on specific metabolites and host genes related to F. prausnitzii from the GutMGene database. Subsequently, a high-fat diet (HFD) was administered to C57BL/6 J mice for 16 weeks. The intragastric injection of F. prausnitzii ATCC 27766 strain was administered and changes in serum and liver metabolic indicators were then assessed. Fecal short-chain fatty acids (SCFAs) were measured using Gas chromatography-mass spectrometry (GC–MS). RNA-sequence (RNA-seq) was performed to identify differentially expressed genes related to F. prausnitzii treatment.
resultsIn individuals with obesity, MASLD, and Type 2 diabetes, the abundance of F. prausnitzii was significantly reduced by 22.4%, 16.2%, and 34%, respectively, compared to healthy controls (all p-values < 0.05). In comparison to HFD-fed control mice, those administered F. prausnitzii exhibited a substantial reduction in liver index (17.5%, p < 0.05), along with a 17.6% decrease in serum total cholesterol (TC) and a 12.7% decrease in triglycerides (TG) (all p-values < 0.05). Additionally, there was a substantial increase in the serum interleukin-10 (IL-10, 20.6%) levels and reduction in expressions of pro-inflammatory cytokines, including interleukin-1α (21.1%), IL-2 (32.2%), IL-5 (18.4%), and IL-6 (29.6%). GC–MS analysis confirmed a 91.4% increase in total fecal SCFAs concentrations, including acetic (91.9%), propionic (93.8%), and butyric acids (93.0%), with all p-values < 0.01. Both RNA-seq and polymerase chain reaction analyses consistently identified substantial changes in genes associated with de novo lipogenesis (Srebp-1c, Fas, Acc), fatty acid oxidation (PPARα, Acadvl, Acadm and Cpt2), and oxidative phosphorylation (Cox5b, Sdhb), with all p-values < 0.01.
conclusionThis study highlights the promise of F. prausnitzii ATCC 27766 strain, especially regarding its anti-inflammatory and metabolic regulatory functions, as a next-generation probiotic agent in prevention and treatment of MASLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.